Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUB-040 combination study in recurrent platinum-sensitive ovarian cancer
2025-524691-33-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of TUB-040 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Occurrence and severity of treatment-emergent adverse events and Occurrence of dose-limiting toxicities. Planned start Mar 2026; status: authorised.
02
Drugs
TUB-040
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2025-524691-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524691-33-00.